Sam Fazeli

Hello, everybody.

Welcome to another episode of Bloomberg Intelligence Vanguards of Healthcare podcast.

It is the last one of the year for me, but it is with somebody whom I've known for a long, long time.

And it's a real pleasure to get back together, even if it's virtual at the minute.

And these podcasters, you know, we speak with the leaders at the forefront of change in the healthcare industry and no one

is closer to those changes than VCs, and no one's closer to those changes than VCs like Antoine that I've known for years.

So my name is Sam Fazelli, and I'm a former biotech analyst at Bloomberg Intelligence, which is the in-house research arm of Bloomberg.

Now, I'm thrilled to welcome Antoine Papiernique, a managing partner at Sofinova Partners.

Plenty of stuff to talk about.

The seven funds that the group runs, which are

Many more than the first days that I remember Antoine from.

I think probably Sofinova Capital was the first one, I guess.

Sofinova is obviously a leading European life sciences venture capital firm founded in 1972.

So it's slightly younger than me.

Just in 2025, the group raised one and a half billion euros.

So combined with the group that I spoke with yesterday,

few weeks ago that was for beyond this these are these two firms along with eqt uh friends there and quite a few other vcs are at the forefront of leading investments into biotech and they are a european-based healthcare vc but obviously not just europe so almost half of that money that was raised went to the uh sofinova capital six eleven fund sorry eleven wow

Over 500 companies backed since 1972.

Currently over 100 in the portfolio companies in the list.

And a total of about 4 billion euros under management.